PhRMA searching for VP-scientific & medical affairs; Beary to focus on drug regulatory affairs.
Executive Summary
PhRMA SEARCHING FOR VP-SCIENTIFIC & MEDICAL AFFAIRS with a target hiring date of June 1. Former Pharmaceutical Research & Manufacturers of America Senior VP-Medical & Regulatory Affairs John Beary, MD, has assumed the new title of senior VP-drug regulatory affairs. PhRMA describes the change as a result of "our recent strategic planning exercise" which clarified "that our top priority in 1997 is renewal of the Prescription Drug User Fee Act and improvement of FDA." As a result, "Beary has volunteered to focus his energies at PhRMA more intensively on drug regulatory affairs, particularly renewal of PDUFA and the International Conference on Harmonization," PhRMA said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth